All News

ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq
Richard Conway RichardPAConway ( View Tweet)
STAR-RA, CV risk large insurance datax3 tofa vs TNFi all comers: HR 1.01 (0.83-1.23) one CV RF + any MTX: HR 1.24 (0.90-1.69) prev CVD: HR 1.27 (0.95-1.70) not sig but surely okay to say baseline CV risk + tofa makes me a little nervous? @SeoyoungCKim #ACR21 ABST1939 @RheumNow https://t.co/LmmL5zgv9u
David Liew drdavidliew ( View Tweet)
So time for ORAL Surveillance, malignancy and VTE risk. I'll go through some of the key points in this thread #ACR21 ABST1940, ABST1941 @RheumNow https://t.co/pbjM2sFAXz
David Liew drdavidliew ( View Tweet)
Why is there more CHF in #RheumatoidArthritis ? Also dose response between highest inflammation RA the PsA then axSpA then PsO. ?Cytokine profile varying with disease and maybe CRP. Who knows. Abst#1925 #ACR21 @RheumNow https://t.co/JIH3qwkLpx

Links:

Janet Pope Janetbirdope ( View Tweet)

#ACR21 Ab#1940. ORAL Surveillance - Malignancy ▶️Remember: pts had ⬆️ CVD risks incl older, smoker, etc so higher risk group for cancer ⭐️Lung cancer most common ⭐️# to harm ~ 300 ⭐️Older age, current/past smoking were independent risk factors https://t.co/JOKNyYVZfX @RheumNow https://t.co/WeX5uZAubd

Links:

Eric Dein ericdeinmd ( View Tweet)
ORAL Surveillance VTE risk. Significant increase in VTE/PE only at 10mg bd dose. Abstr#1941 #ACR21 @RheumNow https://t.co/WW71syiINE
Richard Conway RichardPAConway ( View Tweet)
Sick Leave in axSpA: Who takes more? Dr. Rachel Tate ( @uptoTate) reviews abstract 0380 presented at #ACR21. https://t.co/e8cU9rIVB1 https://t.co/ImSjjLK15m

Links:

Dr. John Cush RheumNow ( View Tweet)
@drhalafadhil @ACRheum @nighat @DrDavidKarp (ACR President) who can we contact at ACR who can help mentor her? I believe there is session #GlobalRheumatologySummit that addresses this. @rheumnow #ACR21 #RheumatologyforAll

TheDaoIndex KDAO2011 ( View Tweet)

Nature or nurture or both? Genesis #scleroderma US cohort showed Hispanic pts had more RNP, more #SLE overlap & younger but ⬆️mortality vs whites but less mortality vs blacks. Health disparities? Abst#1839 #ACR21 @RheumNow https://t.co/pgYJEXP1fN
Janet Pope Janetbirdope ( View Tweet)
#ACR21 #Abstr1913 What do our patients think about #Telemedicine?GRA Registry (N=596; 50% RA and #lupus): 💠Most found => effective than In-Person 💠25% dissatisfied and not keen to continue post-COVID 💠Poor predictors: Age, 🇬🇧🇨🇦🇦🇺🇳🇿, Graduates @RheumNow https://t.co/55UmppwF9P https://t.co/9AyYB4hI3V

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Guselkumab in Psoriatic Arthritis Dr. Pedro Castillo ( @_Castillo_Pedro) discuss three abstracts presented at #ACR21 that expand on the use of guselkumab for use with psoriatic arthritis. https://t.co/hAbLTU4epW https://t.co/p33p6iysjX

Links:

Dr. John Cush RheumNow ( View Tweet)
It was real... no sugar coating... the pandemic was tough... But no match for these women! You can watch on demand. @ACRrheum #ACR21 @rheumnow @bmsnews https://t.co/M4YegqJ5mt

Links:

TheDaoIndex KDAO2011 ( View Tweet)

Should we be measuring drug levels in pts taking infliximab? ⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO) #ACR21 Abs#1946 #ACRBest @RheumNow https://t.co/sWMen50ljP https://t.co/F4Wpqis3id

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Prospective study of PsO screened @ derm clinics 🔹PsO➕>3 mo back pain starting <45yo➕no biologics➡️rheum ref, 100 pts seen➡️19 dx'ed as: 🔹14 axPsA, 68% met axSpA ASAS, 11/14 w/o pPsA 🔹5 pPsA w/o axial dz https://t.co/azoks5CHCP #ACR21 Abst#1796 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Anti-MAA Ab is not ‘baa’ humbug. In prevalent #RheumatoidArthritis, + MAA Ab was predictive of developing #RA #ILD. ? Novel biomarker. Needs validation but nice convincing data @RheumNow #ACR21 #ACRBest abst#1916 https://t.co/wuTPzSIsey

Links:

Janet Pope Janetbirdope ( View Tweet)

#ACR21 2022 ACR/EULAR MPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical: negative for nasal GPA symptoms ⭐️Lab: +6 for pANCA or MPO, negative for cANCA/PR3 or eosinophilia @RheumNow https://t.co/6YWmabNzuH https://t.co/XVzBF2KONp

Links:

Eric Dein ericdeinmd ( View Tweet)
Elevated CRP levels (>3) in PsA associated with ⬆️risk of cardiovascular events ⭐️NSAID use significantly REDUCED risk of CV events Abs#1920 #ACR21 @RheumNow https://t.co/gIz9f4SlWo https://t.co/V4uDeO3Iuz

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Racial differences in PsA patients in large US real world database 95% Whites (W) and 5% were AA NSAIDs: 80% W and 78% AAs TNFI: 51% W and 41% of AAs DMARDs: 72% of W and 98% of AAs HTN/DM/Obesity/Gout 🔼 AA Cancer/osteoporosis /anxiety 🔼 whites Abst#1780 #ACR21 @Rheumnow https://t.co/7ee4bVU7ZA
swethaann23 swethaann23 ( View Tweet)
Another study linking long term GC and CV risk in RA! Medicare data >65yo 130000+ pts 1-year incidence CV ⬆️ as follows: 📍Dose ≤5mg 1.4% 📍Dose 5-10mg 1.7% 📍Dose >10mg 1.9% Not replicated in younger pts (Optum data) #ACR21 #Abst1915 @RheumNow https://t.co/DLXdfvfiBW
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR21 2022 ACR/EULAR EGPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical: obstructive airway, polyps, MM ⭐️Labs: eosinophilia & extravasc eos-inflamm bx, negative points for Hematuria, cANCA or PR3 - Least sensitive: 85%, but 99% specific @RheumNow https://t.co/6YWmabNzuH https://t.co/kLVqXzNTEf

Links:

Eric Dein ericdeinmd ( View Tweet)
×